With regard to SGLT2i versus other antihyperglycemic agents, SGLT2i were associated with a reduced risk of HHF compared to dipeptidyl peptidase 4 inhibitors (DPP4i) and canagliflozin was associated with a reduced risk of HHF and a similar risk of MI or stroke compared to DPP4i, glucagon-like peptide-1 agonists, and sulfonylureas [53, 54]. This evidence concerns the gene GCG and Stroke.